Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_assertion type Assertion NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_head.
- NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_assertion description "[Lastly, the EMX2-high mRNA expressing group had statistically significant better recurrence-free survival (RFS) than the EMX2-low mRNA expression group in patients with adenocarcinoma (P < .001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_provenance.
- NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_assertion evidence source_evidence_literature NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_provenance.
- NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_assertion SIO_000772 21726823 NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_provenance.
- NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_assertion wasDerivedFrom befree-20140225 NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_provenance.
- NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_assertion wasGeneratedBy ECO_0000203 NP822782.RAAxRy73NBZjuNS5ELaVBgwq9BXXoSqcmb7Y-k7bNtMB0130_provenance.